Clinical trials: Neoadjuvant Radiotherapy
Esophageal Cancer
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544362
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 13 sites in France
- Volunteers
- 33 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Advanced Esophageal Squamous Cell Cancer
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
This study aimed to evaluate the safety and feasibility of neoadjuvant tislelizumab combined with chemoradiotherapy in patients with resectable esophageal squamous cell cancer.
- Trial name
- NCT05323890
- Testing
- Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Cancer Hospital and Institute
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the…
- Trial name
- NCT07700420
- Testing
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Rectal Cancer
Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR
The goal of this clinical trial is conducted to evaluate the neoadjuvant regimen of short-course radiotherapy (SCRT) followed by NALIRIFOX chemotherapy plus Pucotenlimab immunotherapy for high-risk locally advanced rectal cancer.
- Trial name
- NCT07651007
- Testing
- iTNT-HX02
- Volunteers
- 29 people
- Sponsor
- Wang Xin
Rectal Cancer
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
- Trial name
- NCT04543695
- Testing
- Concurrent Chemoradiotherapy, XELOX, mFOLFOX
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX
Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer
Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging
- Trial name
- RECTUM2015 (NCT05378919)
- Testing
- Radiotherapy 50 Gy, Fluorouracil/folic acid, Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
- Where
- Lithuania
- Volunteers
- 250 people
- Sponsor
- Lithuanian University of Health Sciences
Soft Tissue Sarcomas
Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS
To date, the radiation oncologist are missing biomarkers predictive of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule.
- Trial name
- RADIOSARC (NCT05739084)
- Testing
- pre-operative radiation, Standard surgery after rpreoprative radiation
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Leon Berard
Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
This single-arm, single-center phase II trial evaluates the safety and efficacy of a non-continuous radio-immunotherapy strategy for recurrent nasopharyngeal carcinoma (NPC) unsuitable for surgery.
- Trial name
- REDEFINE (NCT07277764)
- Testing
- High-Low Dose Radiotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Radiation Oncology
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
The primary objective is to compare surgery with postoperative radiotherapy (PORT) versus surgery, in terms of the overall survival time (OS) in Stage II or III squamous cell esophageal carcinoma with neoadjuvant…
- Trial name
- NCT03734952
- Testing
- Neoadjuvant Radiotherapy Program:, Neoadjuvant chemotherapy Program, Esophagectomy program:
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Fujian Medical University Union Hospital
Non-small Cell Lung Cancer
CT Perfusion Scans for Assessment of Lung Cancer Before and After Chemo +/- Radiotherapy
Cancer of the lung is treated with surgery, radiation or chemotherapy, depending on the stage or extent of the disease. Some patients are treated with chemotherapy and/or radiation therapy before surgery to improve the results of…
- Trial name
- NCT00188214
- Testing
- contrast-enhanced dynamic CT perfusion study
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University Health Network, Toronto
Rectal Cancer, Advanced Stage Colorectal Cancer
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer.
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT07284992
- Testing
- short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Shandong Provincial Hospital
Colorectal Liver Metastases
Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases
The efficiency of T cell based immunotherapies is affected by the insufficient migration and activity of tumor specific effector T cells in the tumor.
- Trial name
- NCT01191632
- Testing
- one time radiation, No Radiation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Heidelberg University
Stage IB Breast Cancer, Stage II Breast Cancer
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells.
- Trial name
- NCT01872975
- Testing
- regional nodal XRT, chestwall XRT, WBI
- Where
- 514 sites in United States, Canada and 5 more
- Volunteers
- 1,636 people
- Sponsor
- NSABP Foundation Inc
Rectal Neoplasms
Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer
This study will assess the complete clinical response (no clinical evidence of remaining disease or recurrence of disease)in rectal cancer that arises within 3 inches of the anal opening after radiation therapy given at the same…
- Trial name
- NCT01613469
- Testing
- 5FU/Leucovorin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Marks, John, M.D.
Resectable NSCLC
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC
This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.
- Trial name
- NCT07050056
- Testing
- Tislelizumab, 3D-CRT/IMRT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Rectal Cancer, Advanced Solid Tumor
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
- Trial name
- NCT06577194
- Testing
- Sintilimab + IL-2 Combined with CAPOX, Short-course radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT).
- Conditions
- Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy, Radiotherapy
- Trial name
- NCT06758830
- Testing
- Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy
- Where
- Lithuania
- Volunteers
- 400 people
- Sponsor
- National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
A standard treatment for pancreatic cancer is radiation therapy plus chemotherapy after surgery. Radiation therapy and chemotherapy are commonly given for up to six weeks.
- Trial name
- NCT00438256
- Testing
- Proton Beam Radiation, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Rectal Cancer
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer
This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) followed by chemoradiotherapy and…
- Trial name
- IXOr (NCT01237665)
- Testing
- IXO regimen
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Hospital Research Institute